Glycogen synthase kinase 3β (GSK-3β) inhibitors - a patent update (2019–2024)

Although many heterocyclic compounds from natural as well as synthetic origin have shown promising inhibitory effects against GSK-3β, most of them have not yet progressed to the development stage. However, a critical review of their structures and biological profiles reveals significant potential for further development.